急性肺傷害(Acute Lung Injury):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Acute Lung Injury - Pipeline Review, H2 2014
◆商品コード:GMDHC5683IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:99
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における急性肺傷害(Acute Lung Injury)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・急性肺傷害(Acute Lung Injury)の概要
・急性肺傷害(Acute Lung Injury)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・急性肺傷害(Acute Lung Injury)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・急性肺傷害(Acute Lung Injury)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・急性肺傷害(Acute Lung Injury)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Acute Lung Injury – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Acute Lung Injury – Pipeline Review, H2 2014’, provides an overview of the Acute Lung Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Lung Injury Overview 10
Therapeutics Development 11
Pipeline Products for Acute Lung Injury – Overview 11
Pipeline Products for Acute Lung Injury – Comparative Analysis 12
Acute Lung Injury – Therapeutics under Development by Companies 13
Acute Lung Injury – Therapeutics under Investigation by Universities/Institutes 15
Acute Lung Injury – Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Acute Lung Injury – Products under Development by Companies 18
Acute Lung Injury – Products under Investigation by Universities/Institutes 20
Acute Lung Injury – Companies Involved in Therapeutics Development 21
Altor BioScience Corporation 21
Apeptico Forschung und Entwicklung GmbH 22
Carolus Therapeutics, Inc. 23
CompleGen, Inc. 24
FirstString Research, Inc. 25
GlaxoSmithKline plc 26
Histocell S.L. 27
Navigen Pharmaceuticals, Inc. 28
Quark Pharmaceuticals, Inc. 29
S-Evans Biosciences, Inc. 30
Silence Therapeutics plc 31
Stemedica Cell Technologies, Inc. 32
Therametrics holding AG 33
Xiber Science GmbH 34
Acute Lung Injury – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
ALT-836 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AP-301 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Atu-111 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Atu-112 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CGX-1037 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CT-2009 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DasKloster-0141-01 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DasKloster-1000–04 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
dilmapimod – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drug to Antagonize LEP-R for Acute Respiratory Distress Syndrome and Acute Lung Injury – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GSK-1995057 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GSK-2586881 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2862277 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HC-016 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Mesenchymal Stem Cells – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer’s Disease – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer’s Disease – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer’s Disease – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
P- BEFizumab – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Peptides to Activate PAI-1 for Acute Lung Injury – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RNAi Oligonucleotide to Activate Protein 53 for Acute Lung Injury – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
S-1229 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
siRNA for Lung Diseases – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Inhibit Arf6 for Multiple Diseases – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Stem Cell Therapy for Acute Lung Injury – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Stem Cell Therapy for Inflammatory Lung Diseases – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Stromal Cell Therapy for Acute Lung Injury – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TAT-SNAP-23 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
TXA-302 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Xib-1301 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Acute Lung Injury – Recent Pipeline Updates 87
Acute Lung Injury – Dormant Projects 92
Acute Lung Injury – Discontinued Products 93
Acute Lung Injury – Product Development Milestones 94
Featured News & Press Releases 94
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 94
Sep 10, 2012: Silence Therapeutics’ Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 94
Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury 95
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 96
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 96
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

[List of Tables]
Number of Products under Development for Acute Lung Injury, H2 2014 11
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Development by Companies, H2 2014 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2014 20
Acute Lung Injury - Pipeline by Altor BioScience Corporation, H2 2014 21
Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2014 22
Acute Lung Injury - Pipeline by Carolus Therapeutics, Inc., H2 2014 23
Acute Lung Injury - Pipeline by CompleGen, Inc., H2 2014 24
Acute Lung Injury - Pipeline by FirstString Research, Inc., H2 2014 25
Acute Lung Injury - Pipeline by GlaxoSmithKline plc, H2 2014 26
Acute Lung Injury - Pipeline by Histocell S.L., H2 2014 27
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 28
Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 29
Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H2 2014 30
Acute Lung Injury - Pipeline by Silence Therapeutics plc, H2 2014 31
Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 32
Acute Lung Injury - Pipeline by Therametrics holding AG, H2 2014 33
Acute Lung Injury - Pipeline by Xiber Science GmbH, H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Acute Lung Injury Therapeutics - Recent Pipeline Updates, H2 2014 87
Acute Lung Injury - Dormant Projects, H2 2014 92
Acute Lung Injury - Discontinued Products, H2 2014 93

[List of Figures]
Number of Products under Development for Acute Lung Injury, H2 2014 11
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Products, H2 2014 17
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Top 10 Targets, H2 2014 36
Number of Products by Stage and Top 10 Targets, H2 2014 36
Number of Products by Top 10 Mechanism of Actions, H2 2014 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 39
Number of Products by Top 10 Routes of Administration, H2 2014 40
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 41
Number of Products by Top 10 Molecule Types, H2 2014 42
Number of Products by Stage and Top 10 Molecule Types, H2 2014 43

【掲載企業】

Altor BioScience Corporation
Apeptico Forschung und Entwicklung GmbH
Carolus Therapeutics, Inc.
CompleGen, Inc.
FirstString Research, Inc.
GlaxoSmithKline plc
Histocell S.L.
Navigen Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
S-Evans Biosciences, Inc.
Silence Therapeutics plc
Stemedica Cell Technologies, Inc.
Therametrics holding AG
Xiber Science GmbH

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[急性肺傷害(Acute Lung Injury):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆